Paper
0
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Authors
Pierluigi Tricoci,Zhen Huang
Claes Held,David Moliterno,Paul Armstrong,Frans Werf,Harvey White,Philip Aylward,Lars Wallentin,Edmond Chen,Myung Jeong,Jinglan Pei,Sergio Leonardi,Tyrus Rorick,A. Kilian,Lisa Jennings,Giuseppe Ambrosio,Christoph Bode,Ángel Cequier,Jan Cornel,Beatriz Díaz‐Molina,Aycan Erkan,Kurt Huber,Michael Hudson,Lixin Jiang,J. Jukema,Basil Lewis,A. Lincoff,Gilles Montalescot,José González‐Juanatey,Hisao Ogawa,Matthias Pfisterer,Juan Prieto,Witold Rużyłło,Peter Sinnaeve,Robert Storey,Marco Valgimigli,David Whellan,Petr Widimský,John Strony,Robert Harrington,Kenneth Mahaffey,Adam DeVore
+41 authors
,Beatriz Dı́az-MolinaPublished
Nov 13, 2011
Show more
Save
Tip0
TipSave
Abstract
Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.